Published Data in Metastatic Neuroendocrine Tumours

SIR-Spheres® Y-90 resin microspheres are an effective treatment for liver metastases of neuroendocrine tumours (mNETs) as first-line therapy or salvage therapy in patients with treatment-refractory disease.

In patients with unresectable progressive or symptomatic and treatment-refractory mNET receiving first-line SIR-Spheres Y-90 resin microspheres (with fluorouracil [5FU]), median OS was generally between 29 to 36 months,1-3 and in the largest study of 148 patients the median OS was 70 months.4 In addition, symptoms were improved in 55% of this patient group,1 and health-related QoL was stable or improved over 24 months.5

SIR-Spheres Y-90 resin microspheres are also an effective salvage therapy for patients with mNET who have failed to respond to other types of medical, surgical, or local ablative treatment modalities (including peptide receptor radionucleotide therapy). In this setting, SIR-Spheres Y-90 resin microspheres may achieve an ORR of 12.5–66.0% across studies,6-9 and TTP and survival rates are encouraging; survival rates of 100%, 57% and 35% have been reported at 1, 3 and 5 years, respectively.6,8

Overall, studies have demonstrated that in patients with treatment-refractory disease as either first-line treatment or salvage therapy for liver metastases, SIR-Spheres Y-90 resin microspheres is efficacious and associated with good tolerability and improvements in health-related QoL.10

Summary of SIR-Spheres Y-90 resin microspheres in mNET

1 King J et al.. Cancer 2008; 113: 921-929.
2 Cao C et al Br J Surg 2010; 97: 537-543.
3 Saxena A et al. Ann Surg 2010; 251: 910-916.
4 Kennedy A.S et al. Am J Clin Oncol 2008; 31: 271-279.
5 McElmurray J H et al. in World Conference on Interventional Oncology 2012; Abs. 47.
6 Kalinowski M et al. Digestion 2009; 79: 137-142.
7 Murthy R et al. J Vasc Interv Radiol 2008; 19: 145-151.
8 Barbier CE et al. Eur J Nucl Med Mol Imaging 2015; 43: 1425-1431.
9 Peker A et al. Diagn Interv Radiol 2015; 21: 54-59.
10 Kennedy A et al. HPB (Oxford) 2015; 17: 29-37.



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage